On this page

Pramosone Cream

hydrocortisone acetate and pramoxine hydrochloride · Cream

Prescription ANDA Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Pramosone Cream
Generic name
hydrocortisone acetate and pramoxine hydrochloride
Dosage form
Cream
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Legacy Pharma USA Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
2
Packages
2
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Hydrocortisone Acetate 10 mg/g 1291082 View
Pramoxine Hydrochloride 10 mg/g 1234532 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
4

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
085368
Application type
ANDA · Abbreviated New Drug Application
Approval date
January 7, 1977
Sponsor
LEGACY
Products on application
1
Submissions recorded
19
Products approved under application 085368.
Product Trade name Form Strength Ingredient Status TE Flags
085368-001 PRAMOSONE CREAM HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE Prescription —

Approval history

Source: Drugs@FDA
Most recent submissions on application 085368.
Type No. Action Status Date Review
Supplement 23 Manufacturing (CMC) Approved December 6, 2001 —
Supplement 22 Manufacturing (CMC) Approved September 21, 2001 —
Supplement 21 Manufacturing (CMC) Approved September 21, 2001 —
Supplement 20 Manufacturing (CMC) Approved February 5, 2001 —
Supplement 19 Manufacturing (CMC) Approved September 21, 2000 —
Supplement 18 Manufacturing (CMC) Approved August 11, 2000 —
Supplement 17 Manufacturing (CMC) Approved March 1, 1999 —
Supplement 16 Manufacturing (CMC) Approved August 20, 1992 —
Supplement 15 Labeling Approved June 3, 1992 —
Supplement 14 Manufacturing (CMC) Approved June 3, 1992 —
Supplement 13 Manufacturing (CMC) Approved June 3, 1992 —
Supplement 11 Labeling Approved June 3, 1992 —
Supplement 12 Manufacturing (CMC) Approved April 27, 1992 —
Supplement 9 Manufacturing (CMC) Approved April 27, 1992 —
Supplement 8 Labeling Approved April 27, 1992 —
Supplement 10 Manufacturing (CMC) Approved November 7, 1988 —
Supplement 7 Manufacturing (CMC) Approved December 21, 1984 —
Supplement 6 Manufacturing (CMC) Approved December 21, 1984 —
Original application 1 Approved January 7, 1977 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250630). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20250630

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE: Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION: Topical corticosteroids are generally applied to the affected area as a thin film three to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS : The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Hypertrichosis Maceration of the skin Itching Acneiform eruptions Secondary infection Irritation Hypopigmentation Skin atrophy Dryness Perioral dermatitis Striae Folliculitis Allergic contact dermatitis Miliaria

Description

openFDA Drug Labeling

DESCRIPTION: Pramosone ® Cream 1% is a topical preparation containing hydrocortisone acetate 1% w/w and pramoxine hydrochloride 1% w/w in a hydrophilic cream base containing stearic acid, cetyl alcohol, Aquaphor ® , isopropyl palmitate, polyoxyl 40 stearate, propylene glycol, potassium sorbate, sorbic acid, triethanolamine lauryl sulfate, and purified water. Topical corticosteroids are anti-inflammatory and anti-pruritic agents. The structural formula, the chemical name, molecular formula and molecular weight for active ingredients are presented below. hydrocortisone acetate Pregn-4-ene-3, 20-dione, 21-(acetyloxy)-11, 17-dihydroxy-, (11-beta)- C 23 H 32 O 6 ; mol.wt.: 404.50 pramoxine hydrochloride 4-(3-(p-butoxyphenoxy)propyl)morpholine hydrochloride C 17 H 27 NO 3 .HCl; mol. wt.: 329.87 image description image description

OVERDOSAGE: Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS. )

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED: Pramosone ® Cream 1% 1 oz tube (NDC 83107-017-1) 2 oz tube (NDC 83107-016-02) Storage Conditions: Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Rx Only. Manufactured for: Legacy Pharma Inc. Georgetown, Cayman KY1-9012 Toll free 1-800-727-7151 Aquaphor® is a registered trademark of Beiersdorf AG. #69038IWK Rev. 01/25 ©2024 Reproduction prohibited

Adverse event reports

Source: openFDA FAERS
73,232
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: HYDROCORTISONE ACETATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
83107-016-02 83107-016 Legacy Pharma USA Inc. 57 g in 1 TUBE (83107-016-02) June 27, 2025
83107-017-01 83107-017 Legacy Pharma USA Inc. 28.4 g in 1 TUBE (83107-017-01) June 27, 2025
83107-016 83107-016 Legacy Pharma USA Inc. — June 27, 2025
83107-017 83107-017 Legacy Pharma USA Inc. — June 27, 2025

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 10 sections on this page.